Sovihep V Tablet

Sovihep V tablet may cause some serious and unwanted side effects that require immediate medical attention; otherwise, it can also lead to a higher risk. Do not forget to discuss the risks and benefits of this medication with your doctor.​
Headache  
Diarrhea  
Nausea  
Difficulty in breathing  
Cough and chills
Loss of appetite  
Muscle pain  
Irregular heartbeat  
Anemia

Take this medicine as prescribed by your doctor. Do not skip or miss your dosing schedule. This medicine can be taken with or without food. In case of an overdose, the doctor will provide emergency medical treatment.  

Sovihep V works by blocking different steps in the reproduction of viruses. Sofosbuvir with Velpatasvir is an oral fixed-dose combination of sofosbuvir, a nucleotide analog NS5B polymerase inhibitor, and Velpatasvir, an NS5A replication complex inhibitor. Sofosbuvir is approved for the treatment of genotype 1, 2, 3, and 4 HCV infection with different regimens and durations depending on the HCV genotype. After the oral administration, the effect of this medicine can be observed in 2 to 4 hours.

It is advisable not to miss a dose of Sovihep V tablet. If you miss a scheduled dose of this medicine, contact your doctor immediately.  

At our pharmacy, your health is our top priority. All of our medicines are safe, effective, and approved by leading health authorities. We partner exclusively with reliable and reputable manufacturers, ensuring the highest quality standards in every product we deliver.

Enjoy the convenience of fast home delivery, secure packaging, and affordable prices—plus special discounts on bulk orders. We’re proud to offer international shipping to a wide range of countries across Asia, Europe, Africa, the Americas, and beyond, making trusted healthcare accessible no matter where you are.

Whether you're a patient or a healthcare provider, you can order with confidence and compassion. Our goal is to ensure that quality healthcare reaches everyone, everywhere.


We currently ship to:

Barbados, Haiti, Trinidad and Tobago, Mexico, Bahamas, Ecuador, Peru, Chile, Brazil, Colombia, Philippines, U.K., USA, Kuwait, Saudi Arabia, UAE, Oman, Qatar, Japan, Ireland, Russia, China, France, Australia, Lithuania, Nigeria, Romania, Algeria, Canada, Singapore, Thailand, Hong Kong, Bahrain, Jordan, Indonesia, Hungary, Moldova, Bulgaria, Azerbaijan, Congo, Ethiopia, Lebanon, Morocco, Mozambique, South Korea, Sri Lanka, Belarus, Mongolia, Malaysia, Vietnam, Tunisia, Zambia, and Israel.
Experience the quality everyone’s talking about – order today!

Feld, J. J., Jacobson, I. M.,Hézode, C., Asselah, T., Ruane, P., Gruener, N., Chan, H. L. Y. (2015). Sofosbuvir and velpatasvir for HCV genotype 1, 2, 4, 5, and 6 infection. New England Journal of Medicine, 373(27), 2599–2607. https://doi.org/10.1056/NEJMoa1512610

Mangia, A., et al. (2020). Global real-world evidence of sofosbuvir/velpatasvir as simple, effective HCV treatment: Analysis of 5,552 patients from 12 cohorts. Liver International. Chandrashekhar, R., et al. (2019). Sofosbuvir–velpatasvir single-tablet regimen administered for 12 weeks in a phase III study with minimal monitoring in India. Hepatology International.

Uemura, Y., et al. (2021). Real‑world clinical application of 12-week sofosbuvir/velpatasvir  treatment for decompensated cirrhotic patients with genotype 1 and 2: a prospective, multicenter study. Journal of Clinical and Experimental Hepatology. (Open access). https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7680481/

Lee, S., et al. (2022). Efficacy and safety of sofosbuvir/velpatasvir ± ribavirin in genotype 3 compensated cirrhosis: a meta-analysis. World Journal of Hepatology, 14(6), 1248–1259. https://doi.org/10.4254/wjh.v14.i6.1248

Takehara, T., Sakamoto, N., Nishiguchi, S., et al. (2019). Sofosbuvir–velpatasvir with or without ribavirin in HCV-infected Japanese patients with decompensated cirrhosis: an open-label phase III trial. Journal of Gastroenterology, 54(1), 87–95. https://doi.org/10.1007/s00535-018-1503-x